Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…

Mees Egeler

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment for…

Alexander van Akkooi

2024 Melanoma Update: Insights Into Sentinel Node Evaluation

Scripps Health

M. Ross

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

Melanoma in the Molecular Age - Part 1: New Tools for Diagnosis, Pro…

Scripps Health

G. Hosler

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

AAD 2024

V. Sondak

Pathology of Melanoma

Scripps Health

B. Kelley

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

2024 ASCO® Annual Meeting Insights Hub

A. Hauschild

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

Utilization of COMBI-APlus Data in Clinical Practice: Adapted Pyrexi…

Northwestern Medicine Oncology and Hematology

S. Chandra